跳至主要内容
临床试验/NCT05441878
NCT05441878Unknown4 期

To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial.

Post Graduate Institute of Medical Education and Research, Chandigarh1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年8月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
150
试验地点
1
主要终点
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)

研究概览

简要总结

Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology who consent for enrolment.
  • Hypotension (Mean arterial pressure <65mmHg or Systolic blood pressure <90mmHg)
  • Aged between18-65 yrs

排除标准

  • Already received colloid or more than 2 litres of fluid without baseline echocardiographic assessment.
  • Already on vasopressors/inotropes
  • Severe pre-existing cardiopulmonary disease
  • Acute Respiratory Distress Syndrome (ARDS)
  • Active bleeding like variceal bleed
  • Cerebrovascular events
  • Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
  • Admission to ICU following liver transplantation, burns, cardiac surgery
  • Brain death or likely brain death within 24 hours
  • Previous adverse reaction to human albumin solution
  • Pregnant or lactating women
  • Informed consent refused by patient or attendants

研究组 & 干预措施

20% Albumin arm

Experimental

20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h

干预措施: Balanced salt solution (Drug)

20% Albumin arm

Experimental

20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h

干预措施: 20% albumin (Drug)

Balanced salt solution arm

Active Comparator

Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of > 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.

干预措施: Balanced salt solution (Drug)

结局指标

主要结局

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)

时间窗: At 48 hours.

To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.

时间窗: At 48 hours.

To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters.

时间窗: At 48 hours.

To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension

次要结局

  • Urinary marker of AKI (NGal)(At enrolment)
  • Change in urinary markers of AKI (NGal)(At 24 hours.)
  • Change in urinary markers of AKI(NGal)(At 48 hours.)
  • To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement(At 24 hours)

研究者

发起方
Post Graduate Institute of Medical Education and Research, Chandigarh
申办方类型
Other
责任方
Principal Investigator
主要研究者

Madhumita Premkumar

Assistant professor, Department of Hepatology

Post Graduate Institute of Medical Education and Research, Chandigarh

研究点 (1)

Loading locations...

相似试验